A Clinical Trial to Evaluate the Efficacy and Safety of a Mixed Extract of a Mixed Extract Including Agastache rugosa(BronchTM) on Respiratory Health

A 12-Week, Randomized, Double-Blind, Placebo-Controlled Human Clinical Trial to Evaluate the Efficacy and Safety of a Mixed Extract Including Agastache rugosa (BronchTM) on Respiratory Health

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0010203

Enrollment

Registered

2025-02-14

Start date

2020-12-09

Completion date

Unknown

Last updated

2025-11-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Dietary Supplement : 1)Test Product (Mixed Extract Including Agastache rugosa (BronchTM)): - Appearance and Form: Yellowish-brown powder / Reddish-brown tablet - Product: 800 mg/day of a mixed extract

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Adult men and women aged 19 to 80 at the time of screening 2) Non-smokers (those who quit smoking at least 3 months prior to the screening) 3) Individuals with at least two persistent respiratory discomfort symptoms (e.g., cough, sputum, shortness of breath, or chest tightness) for more than one month prior to the screening 4) Individuals who have received a detailed explanation of the study, fully understand it, and voluntarily decide to participate by providing written consent to comply with the precautions

Exclusion criteria

Exclusion criteria: 1) Individuals showing signs of airflow limitation in pulmonary function tests (post-bronchodilator FEV1/FVC 3 times the upper limit of the reference range (Serum Creatinine > 2.0 mg/dL) 16) Women who are pregnant, breastfeeding, or planning to become pregnant 17) Women of childbearing age who do not agree to use appropriate contraception 18) Individuals deemed unsuitable for participation in the study by the principal investigator due to diagnostic laboratory results or other reasons

Design outcomes

Primary

Measure	Time frame
Saint George’s respiratory questionnaire (SGRQ);Chronic obstructive pulmonary disease assessment test(CAT) ;Breathlessness, cough, and sputum scale(BCSS)	—

Secondary

Measure	Time frame
pulmonary function test (PFT); Forced vital capacity(FVC), Forced expiratory volume in 1 second(FEV1), FEV1/FVC;(Modified medical research council dyspnea scale(mMRC) ;Inflammatory Markers: hs-CRP (high-sensitivity C-reactive protein), ESR (erythrocyte sedimentation rate);Quality of Life Questionnaire (EuroQol-5 Dimensions, EQ-5D);Wisconsin upper respiratory symptom survey-21(WURSS-21)	—

Countries

Korea, Republic of

Contacts

Public ContactSu-Jin Jung

Jeonbuk National University Hospital

sjjeong@jbctc.org+82-63-259-3044

Outcome results